Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

21. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study

of China. 15 Cliniche Humanitas Gavazzeni, Bergamo, Italy. 16 Merck & Co, Kenilworth, NJ. 17 The Netherlands Cancer Institute, Amsterdam, the Netherlands. PMID: 32078391 DOI: Item in Clipboard Full-text links Cite Abstract Purpose: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) ≥ 50% and ≥ 1%. We report (...) Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History

2020 EvidenceUpdates

22. Radiation Therapy for Small Cell Lung Cancer

irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med . 1999 ; 341 : 476–484 | | | In ES disease, treatment typically involves chemotherapy alone x 9 Green, R.A., Humphrey, E., Close, H., and Patno, M.E. Alkylating agents in bronchogenic carcinoma. Am J Med . 1969 ; 46 : 516–525 | | | with or without PCI. x 10 Slotman, B., Faivre-Finn, C., Kramer, G. et al. Prophylactic cranial irradiation in extensive small (...) will commission a replacement or reaffirmation within 5-years of publication. 1. Introduction Small cell lung cancer (SCLC) is the second most common thoracic malignancy, representing approximately 13% of newly diagnosed lung cancers. x 1 in: N. Howlader, A. Noone, M. Krapcho, (Eds.) SEER Cancer Statistics Review . National Cancer Institute , Bethesda, MD ; 1975-2016 ( Available at: ) . ( Accessed November 22, 2019 ) SCLC is a particularly aggressive malignancy, with only about one-third of patients diagnosed

2020 American Society for Radiation Oncology

23. Lung cancer and mesothelioma service guidance during the COVID-19 pandemic

When indicated, use PET-CT prior to any staging EBUS and to identify alternative biopsy target. o In cases where there is a low risk of mediastinal disease, consider percutaneous lung biopsy or proceeding directly to treatment based on lung cancer probability (including the use of the Herder model) ? Omit contrast enhanced CT brain in clinical stage II lung cancer. ? Do not perform full lung function testing when the clinician and surgeon are happy with simple spirometry. ? Do not perform (...) chemotherapy for patients with mesothelioma to those with epithelioid tumours. 4. Information for Patients Please discuss with all patients undergoing diagnostic and staging tests or being referred for treatment that there are intense pressures on the NHS which may result in longer waits to undergo tests, see specialist clinicians and commence treatment. Please ensure they have contact details of their lung cancer specialist nurses (LCNS) or relevant team to discuss any concerns and seek support

2020 British Thoracic Society

24. ASTRO/ESTRO Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic Full Text available with Trip Pro

ASTRO/ESTRO Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement - ScienceDirect JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page. COVID-19 campus closures: to subscribed content Share Export Available online 6 April 2020 Practice recommendations for lung cancer radiotherapy during the COVID-19 (...) pandemic: An ESTRO-ASTRO consensus statement Author links open overlay panel … Show more Under a Creative Commons open access Highlights • Risk-mitigation pandemic scenario: efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. • Postponement or interruption of radiotherapy of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection

2020 American Society for Radiation Oncology

25. CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours

CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours CIRSE Standards of Practice on Thermal Ablation of Primary and Secondary Lung Tumours

2020 Cardiovascular and Interventional Radiological Society of Europe

26. EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules

EarlyCDT-Lung (Oncimmune) is a blood test that measures a group of 7 autoantibodies (p53, NYESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2) to tumour-associated antigens related to lung cancer. It helps early detection of lung cancer in people with high risk and allows differentiation of benign or malignant nodules. In the early stages of lung cancer, autoantibodies and tumour-associated antigens are produced as the body's immune system's response to cancer antigens. Blood levels of autoantibodies (...) . NICE's guideline on the diagnosis and management of lung cancer recommends sputum cytology for investigation in people with suspected lung cancer who have centrally placed nodules and are unable to tolerate bronchoscopy or invasive tests. A contrast-enhanced chest CT scan is recommended for further diagnosis and to stage the disease. The guideline recommends PET-CT as a first test after CT with a low probability of nodal malignancy (lymph nodes below 10 mm). MRI, endobronchial ultrasound-guided

2020 National Institute for Health and Clinical Excellence - Advice

27. Assessment of preoperative noninvasive ventilation before lung cancer surgery: The preOVNI randomized controlled study

Create file Cancel Actions Cite Share Permalink Copy Page navigation J Thorac Cardiovasc Surg Actions . 2019 Nov 23;S0022-5223(19)33106-X. doi: 10.1016/j.jtcvs.2019.09.193. Online ahead of print. Assessment of Preoperative Noninvasive Ventilation Before Lung Cancer Surgery: The preOVNI Randomized Controlled Study , , , , , , , Collaborators, Affiliations Expand Collaborators GFPC Group : , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations 1 Respiratory Disease Unit, HIA (...) Respiratory Disease Unit, HIA Sainte Anne, Toulon, France. PMID: 31924365 DOI: Item in Clipboard Assessment of Preoperative Noninvasive Ventilation Before Lung Cancer Surgery: The preOVNI Randomized Controlled Study Nicolas Paleiron et al. J Thorac Cardiovasc Surg . 2019 . Show details J Thorac Cardiovasc Surg Actions . 2019 Nov 23;S0022-5223(19)33106-X. doi: 10.1016/j.jtcvs.2019.09.193. Online ahead of print. Authors , , , , , , , Collaborators GFPC Group

2020 EvidenceUpdates

28. Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non–Small Cell Lung Cancer

: about 60% of NSCLCs are adenocarcinoma. Former or current smoking is often a causal factor in all forms of lung cancer. However, nonsmokers with lung cancer frequently have adenocarcinoma. This type of cancer is usually found on the outer parts of the lung. People with adenocarcinoma tend to have better survival than people with other types of lung cancer • Squamous cell (epidermoid) carcinoma: 25% to 30% of all NSCLCs are squamous cell carcinomas. Squamous cells are flat cells that line the inside (...) • Other subtypes: Less common NSCLC subtypes include adenosquamous carcinoma and sarcomatoid carcinoma The progression of cancer is divided into four stages; a higher number signifies more extensive disease. In stage 1, the cancer is confined to the original site within the lung and there is no sign of spread to lymph nodes (N0) or elsewhere (M0). In stage 2, the cancer has spread to lymph nodes within the lung (N1). In stage 3, the cancer has spread to lymph nodes in the middle of the chest

2020 Health Quality Ontario

29. Lorlatinib (Lorviqua) - non-small cell lung cancer (NSCLC)

(Lorviqua ® ) is accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment. Indication under review: as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI In the relevant subgroup of a non-comparative (...) Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: 1 ? alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or ? crizotinib and at least one other ALK TKI Dosing Information The recommended dose is 100mg lorlatinib taken orally once daily. Treatment with lorlatinib

2020 Scottish Medicines Consortium

30. Effect of lidocaine cream analgesia for chest drain tube removal after video-assisted thoracoscopic surgery for lung cancer: a randomized clinical trial (Abstract)

Effect of lidocaine cream analgesia for chest drain tube removal after video-assisted thoracoscopic surgery for lung cancer: a randomized clinical trial Pain management makes an important contribution to good respiratory care and early recovery after thoracic surgery. Although the development of video-assisted thoracoscopic surgery (VATS) has led to improved patient outcomes, chest tube removal could be distressful experience for many patients. The aim of this trial was to test whether (...) the addition of lidocaine cream would have a significant impact on the pain treatment during chest tube removal from patients who had undergone VATS for lung cancer.This clinical trial was a double-blind randomized study. Forty patients with histologically confirmed lung cancer amenable to lobectomy/segmentectomy were enrolled. All patients had standard perioperative care. Patients were randomly assigned to receive either epidural anesthesia plus placebo cream (placebo, Group P) or epidural anesthesia plus

2020 EvidenceUpdates

31. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer (Abstract)

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non-small-cell lung cancer (NSCLC).The study used a 2 × 2 factorial design with radiation dose as 1 factor and cetuximab as the other, with a primary end point (...) survival (PFS) rates were 32.1% and 23% and 18.3% and 13% (P = .055), respectively. Factors associated with improved OS on multivariable analysis were standard radiation dose, tumor location, institution accrual volume, esophagitis/dysphagia, planning target volume and heart V5. The use of cetuximab conferred no survival benefit at the expense of increased toxicity. The prior signal of benefit in patients with higher H scores was no longer apparent. The progression rate within 1 month of treatment

2020 EvidenceUpdates

32. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline (Abstract)

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non-small-cell lung cancer (NSCLC) and SCLC.ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology, primary care, and advocacy experts to conduct a literature (...) for this guideline.Patients should undergo surveillance imaging for recurrence every 6 months for 2 years and then annually for detection of new primary lung cancers. Chest computed tomography imaging is the optimal imaging modality for surveillance. Fluorodeoxyglucose positron emission tomography/computed tomography imaging should not be used as a surveillance tool. Surveillance imaging may not be offered to patients who are clinically unsuitable for or unwilling to accept further treatment. Age should not preclude

2020 EvidenceUpdates

33. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. (Abstract)

Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. There are limited data from randomized trials regarding whether volume-based, low-dose computed tomographic (CT) screening can reduce lung-cancer mortality among male former and current smokers.A total of 13,195 men (primary analysis) and 2594 women (subgroup analyses) between the ages of 50 and 74 were randomly assigned to undergo CT screening at T0 (baseline), year 1, year 3, and year 5.5 or no screening. We (...) obtained data on cancer diagnosis and the date and cause of death through linkages with national registries in the Netherlands and Belgium, and a review committee confirmed lung cancer as the cause of death when possible. A minimum follow-up of 10 years until December 31, 2015, was completed for all participants.Among men, the average adherence to CT screening was 90.0%. On average, 9.2% of the screened participants underwent at least one additional CT scan (initially indeterminate). The overall

2020 NEJM

34. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer Osimertinib for untreated EGFR mutation-positive non- small-cell lung cancer T echnology appraisal guidance Published: 22 January 2020 www.nice.org.uk/guidance/ta621 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 19Contents Contents 1 Recommendations 4 2 Information about osimertinib 5 Marketing authorisation

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

35. Pembrolizumab (Keytruda) - Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma

Pembrolizumab (Keytruda) - Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you

2020 Health Canada - drugs and medical devices

36. Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations

,EasternCooperativeOncologyGroup; EGFR,epidermalgrowthfactorreceptor;IHC,immunohistochemistry;N/A, notapplicable;NSCLC, non–small-cell lung cancer; PD-L1, programmed death ligand 1; PS, performance status; SCC, squamous cell carcinoma; Teff, T effector; TPS, tumor proportion score. Journal of Clinical Oncology 7 Systemic Therapy for Stage IV NSCLC Guideline UpdatePatients with cancers with sensitizing EGFR or ALK alter- ations were excluded from the trial. The study’s primary outcomeswereOSandPFS.OSintheinterventionarmwas (...) Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations ASCO special articles TherapyforStageIVNon–Small-CellLungCancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update Nasser H. Hanna,MD 1 ; Bryan J. Schneider,MD 2 ; Sarah Temin, MSPH 3 ; Sherman Baker Jr, MD 4 ; Julie Brahmer,MD 5 ; Peter M. Ellis, MD, PhD 6 ; Laurie E. Gaspar, MD, MBA 7,8 ; Rami Y. Haddad,MD 9 ; Paul J. Hesketh,MD 10 ; Dharamvir Jain,MD 11 ; Ishmael Jaiyesimi,MD 12 ; David H. Johnson,MD

2020 Cancer Care Ontario

37. Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations

Guideline Update Guideline Question What systemic therapy treatment options should be offered to patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations, depending on the subtype of the patient’s cancer? Target Population Patients with stage IV NSCLC without driver alterations in epidermal growth factor receptor ( EGFR ) or anaplastic lymphoma kinase ( ALK ) (with known EGFR and ALK ) status (plus programmed death ligand 1 (PD-L1) tumor proportion score (TPS) test results (...) Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.03022 Journal of Clinical Oncology - published online before print January 28, 2020 PMID: Therapy for Stage IV Non

2020 American Society of Clinical Oncology Guidelines

38. Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) Atezolizumab with carboplatin and nab- paclitaxel for untreated advanced non-squamous non- small-cell lung cancer (terminated appraisal) T echnology appraisal guidance Published: 15 January 2020 www.nice.org.uk/guidance/ta618 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents (...) Contents Advice 3 Information 3 Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small- cell lung cancer (terminated appraisal) (TA618) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make a recommendation about the use in the NHS of atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

39. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

, multicentre, double-blind, randomised, controlled, phase 3 trial. Eligible patients were aged at least 18 years, had a WHO performance status of 0 or 1, with histologically or cytologically documented stage III, unresectable non-small-cell lung cancer, for which they had received at least two cycles of platinum-based chemoradiotherapy, with no disease progression after this treatment. We randomly assigned patients (2:1) using an interactive voice response system and a blocked design (block size=3 (...) Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study Patient-reported Outcomes With Durvalumab After Chemoradiotherapy in Stage III, Unresectable Non-Small-Cell Lung Cancer (PACIFIC): A Randomised, Controlled, Phase 3 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed

2020 EvidenceUpdates

40. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several (...) than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 38 (2), 115-123 2020 Jan 10 Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1

2020 EvidenceUpdates